Lymphoma | Medical XPRT
Articles & Whitepapers
-
Clonality Analysis Service: A Paradigm Shift in Disease Diagnosis and Treatment
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of cancerous cells in a ...
-
CD19: One of The Most Important Targets for Car-T Cell Therapy
What is CD19 Understanding CD19: Definition and Role in the Immune System CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It ...
News
-
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New ...
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
Equipment & Solutions
-
Showcase
Flow Cytometry Control
CD-Chex CD103 Plus is the only commercially available flow cytometry control that includes CD103, CD30, CD38, CD56, CD138 and cytoplasmic Lambda. It is a unique, positive procedural control with two distinct abnormal leukocyte populations: CD45+ and CD45-.